Expression Analysis in partnership with Complement Genomics to offer
genomic services in UK
16 February 2009
Expression Analysis, Inc., a provider of genomic services for
clinical trials and research, has entered into a partnership with
Sunderland, UK-based Complement Genomics Ltd to offer its genomic
services to the UK market.
The company's Geneblitz unit offers state-of-the-art molecular
services to pharmaceutical companies, government agencies, universities
and research institutes. The partnership will give Expression Analysis
access to these clients in the UK and will allow both companies to
expand their service offerings.
“The partnership with Geneblitz provides us an established presence
in the United Kingdom, with an experienced service provider who operates
with the same philosophy and similar quality standards and platforms,”
stated Steve McPhail, President and CEO of Expression Analysis. "Geneblitz
will focus its efforts on genome-wide association studies which have
become an increasingly larger part of our business," continued McPhail.
“Expression Analysis is an industry leader with a great reputation in
the field of genomic services and our decision to partner with them was
not a difficult one,” said Louise Allcroft, Chief Executive Officer of
Complement Genomics Ltd. “By combining our experience, scientific
leadership and high-throughput capabilities, we will be able to help
meet the needs of the extensive pharmaceutical and biotechnology
infrastructure in the United Kingdom.”
Bookmark this page